FRESHReport written today · at $10.34

RGNX

SpeculativeSMALL CAP

REGENXBIO Inc. · NASDAQ · Healthcare / Gene Therapy (Rare Disease)

$10.34

▲ 0.19%

MCap $534.57M

Self-fetched today (no live-prices.json cache yet). Roughly flat today, but up sharply since the Jun 22, 2026 FDA reversal news (a same-day pop of up to 37% premarket) that reopened the accelerated-approval path for NAVSUNLI after a Feb 2026 Complete Response Letter had sent shares down 21%.

BusinessAAV gene therapy developer · NAVSUNLI (RGX-121) for Hunter syndrome cleared an FDA course-reversal on its Feb 2026 CRL · RGX-202 Duchenne + AbbVie wet-AMD collaboration in the pipeline

Thesis

REGENXBIO's Hunter syndrome gene therapy NAVSUNLI (RGX-121) got a rare FDA course-reversal: after a February 2026 Complete Response Letter (-21% on the stock), the FDA has now aligned with the company that its existing clinical data is sufficient for the accelerated approval pathway — no new patients or studies required. A Type A meeting is expected this month (July 2026) with BLA resubmission targeted rapidly after, in Q3 2026. All 11 covering analysts rate the stock Buy with a $24.36 consensus target (+136% from here), though individual targets range widely ($10-50), reflecting real disagreement on timeline and probability, not just size. A second, separate catalyst — the RGX-202 (Duchenne) BLA submission — adds optionality but isn't the near-term driver. This is a binary regulatory-pathway stock: real upside, real prior failure on the record.

📝 Primary Verdict · Core Holding

SPECULATIVESpeculative

SPECULATIVE — small position ahead of the July Type A meeting, add on a dip toward $8.50-9.00. Real FDA course-reversal, but a second setback is a genuine risk, not a tail case.

81

score / 100 ⓘ

⚡ Catalyst

🧬 FDA Type A Meeting (NAVSUNLI Path Forward)THIS MONTH

REGENXBIO expects to hold a Type A meeting with the FDA in July 2026 to finalize the resubmission path for NAVSUNLI (RGX-121) in Hunter syndrome, following the FDA's alignment that existing data supports accelerated approval without new patients or an untreated control arm.

Jul 2026

📄 NAVSUNLI BLA ResubmissionQ3 2026

Company plans to resubmit the BLA rapidly following the Type A meeting, targeted for Q3 2026, with the FDA committing to an expedited review. A clean resubmission (no further amendments required) would be the next major de-risking step toward approval.

Q3 2026

💊 RGX-202 (Duchenne) BLA PathwayONGOING

Separate program: the AFFINITY DUCHENNE Phase III portion met its primary endpoint (93% of patients above 10% microdystrophin expression), supporting an accelerated-approval BLA strategy and a potential 2027 commercial launch — independent optionality alongside the NAVSUNLI catalyst.

H2 2026

🎯 Entry Point

Entry 1

$10.34

Current price — well off the Jun 22 pop highs, consolidating ahead of the Type A meetingNow (small)

Entry 2PREFERRED

$8.5–9

Pre-Jun 22 base — best R/R if the stock retraces before the Type A meeting newsIf dips

Entry 3

$6.50

Near the low end of the post-CRL range — only on a broad biotech selloff with no new company-specific bad newsDeep dip only

✅ Take Profit

TP1

Base — Type A meeting confirms the resubmission path cleanly

$16.03

+55%

TP2

Bull — clean BLA resubmission in Q3 with FDA acceptance, hits consensus target

$24.36

+136%

TP3 🌙

Moon — resubmission accepted + approval trajectory confirmed, hits Stifel's target

$42

+306.2%

🔴 Stop Loss

Tight Stop

Below the pre-Jun 22 consolidation zone — thesis-neutral but momentum breaking down

$7.8

-10.9%

Hard Stop

Deep breach — a second FDA rejection or major amendment request would mirror the Feb 2026 CRL reaction

$6

-31.5%

Risk / Reward

From Entry 2 ($8.75 mid) tight stop vs TP2

18.9 : 1

⚠ Very high R/R but this is a binary regulatory stock with a real prior CRL on the record — small size mandatory

📅 Estimate Date

FDA Type A Meeting

Company-guided timing, exact day not yet public

Jul 2026

Outcome expected to confirm resubmission path

NAVSUNLI BLA Resubmission

Targeted rapidly following the Type A meeting

Q3 2026

FDA has committed to expedited review

📈 Stock Timeline

1 snapshot · Jul 22

First snapshot — check back next week

Score

73

Jul 22

TP2 Target

$24.36

Jul 22

Rank

#27

Jul 22

📈 Possible Up % — Scenario Spread

Bear

-30%

$7.24

Base

+55%

$16.03

Bull

+136%

$24.36

Moon

+306%

$42

← downsideupside →

🏛️ Fed / Macro Risk — MEDIUM

Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution

Rate Outlook

Fed holds at 3.50–3.75%, but new Chair Warsh's hawkish tone has 9 of 18 officials projecting a further 2026 hike, with the next FOMC decision Jul 28–29, 2026 — just days after this report.

Inflation

Core inflation remains above target and the 10-year yield sits near 4.48% — a headwind for small-cap biotechs that periodically need to raise capital before reaching profitability.

Sector Impact

Biotech regulatory catalysts are largely macro-independent — an FDA decision doesn't care about interest rates — but a small-cap name that may need financing before commercialization is more exposed to a high-rate environment raising the cost of that capital.

Summary

MEDIUM — the FDA pathway itself is idiosyncratic and macro-independent, but REGENXBIO's small-cap size and pre-revenue balance sheet mean a hawkish surprise at the Jul 28-29 FOMC or a broader risk-off move would still pressure the stock independent of the regulatory news flow.

🎯 Analyst Targets

Wall Street price targets vs the current price — cross-check our TP levels

Consensus (11 analysts)

Buy$24.36+136%

Stifel Nicolaus

Buy$42+306%

Robert W. Baird

Buy$32+209%

H.C. Wainwright

Buy$26+151%

Leerink Partners

Buy$17+64%

Morgan Stanley

Buy$16+55%

current price $10.34

🔍 Similar-Catalyst Comparable Check

Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic

RGNX✅ GoodJun 2026

+37%

in 1 day

FDA alignment/reversal on NAVSUNLI accelerated-approval pathway

Same-company, same-program precedent for exactly this catalyst type — the strongest available comparable for the Type A meeting and BLA resubmission ahead.

RGNX❌ BadFeb 2026

-21%

in 1 day

FDA Complete Response Letter for RGX-121/NAVSUNLI

The exact same-program risk case — shows what a second adverse FDA decision would look like for this stock, directly relevant given the binary nature of the upcoming catalysts.

QURE❌ Bad2026

-15%

in 1 day

uniQure's AMT-130 (Huntington's gene therapy) — FDA reversed a prior accelerated-approval alignment

Cross-company gene-therapy comparable showing the FDA's inconsistent 2026 track record on accelerated-approval alignments for this modality — the same regulatory uncertainty applies to RGNX's path.

⚡ Optional Layer · Tactical Overlay

🎯 Catalyst Spot Mode

Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.

⚠️

Use this stop-loss set (-11% / -20%) only when trading the earnings spot — not for the core holding (use the -10.9% / -31.5% set above). If you are holding long-term, follow the core set.

📈Pre-Catalyst Run-up Pattern

minimal pre-event drift; the move happens on the news itselfsame-day on FDA correspondence, not a multi-week runup

Small-cap gene-therapy names in this cohort react same-day to FDA correspondence rather than grinding up beforehand — REGENXBIO's own Jun 22, 2026 pop happened immediately on the reversal news, with no meaningful multi-week runup beforehand.

🎲Historical Post-Catalyst Move

✅ Catalyst Winavg +37%

range: +30% to +100%+· Jun 2026 (RGNX)

REGENXBIO's own Jun 22, 2026 FDA alignment/reversal news drove a premarket pop of up to 37%. General biotech sector pattern for small-cap approval/positive-regulatory-news events runs 30-100%+ depending on how much was already priced in.

❌ Catalyst Missavg -21%

range: -15% to -40%· Feb 2026 (RGNX)

REGENXBIO's own Feb 2026 Complete Response Letter for the same NAVSUNLI program sent shares down 21% (from $10.62 to $8.40) in a single session — the exact same-company, same-program precedent for what a second setback would look like. General sector CRL reactions run -40% to -80% for less-de-risked names.

💼Spot Position Sizing

How the recommended % is derived

3%

of portfolio

Small-cap ($534M) binary regulatory stock with a real prior CRL on the same program — 3% sizing keeps meaningful upside exposure without over-concentrating in a name that's already shown it can drop >20% in a session.

🛑Stop Loss · Spot Trade

Spot cut-loss levels — separate from the core holding

Before Catalyst

-11%($7.8)

Below the pre-Jun 22 consolidation zone ahead of the Type A meeting — thesis-neutral but momentum breaking down

After Catalyst (Bad Result)-20%

A second FDA rejection or a new major-amendment request would mirror the Feb 2026 CRL reaction — exit

📎 Sources

https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-alignment-fda-path-forward-navsunlitm-bla https://www.pharmaceutical-technology.com/news/fda-changes-rare-disease-tune-again-as-it-clears-path-for-regenxbios-gene-therapy/https://www.fiercebiotech.com/biotech/another-reversal-rare-disease-fda-reconsider-regenxbio-gene-therapy https://www.biospace.com/fda/regenxbio-to-resubmit-application-for-hunter-gene-therapy-after-fdas-most-recent-pivot https://stockanalysis.com/stocks/rgnx/forecast/https://stockanalysis.com/stocks/rgnx/

Generated 2026-07-22 · Not financial advice